CAPLIN POINT LABORATORIES LTD. (CAPLIPOINT.BO)

1,380.40 -18.05 (-1.29%) At close: 03:56PM IST

CAPLIN POINT LABORATORIES LTD.

Ashvich Tower
3rd Floor No.3, Developed Plots Industrial Estate Perungudi
Chennai 600096
India
91 44 2496 8000
https://www.caplinpoint.net

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Sridhar Ganesan	MD & Whole Time Director	8.7M	N/A	1955
Mr. D. Muralidharan	Chief Financial Officer	9.7M	N/A	N/A
Mr. Partheeban Vivek Siddarth	Chief Operating Officer	N/A	N/A	N/A
Mr. G. Venkatram	General Counsel, Company Secretary & Compliance Officer	N/A	N/A	1982
Mr. M. Sathya Narayanan	Deputy Chief Financial Officer	N/A	N/A	N/A
Mr. Ashok Gorekey Partheeban	Head of Marketing - Latam Business	N/A	N/A	N/A
Mr. Thiagaraja Manikandan	Chief Transformation & Digital Officer	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in INR.

Description

Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic pharmaceutical formulations and branded products in India. It provides liquid and lyophilized vials, pre-filled syringes, 3-pc ophthalmic droppers, pre-mix bags, dry and liquid syrups-bottles, tables, soft gels, capsules, suppositories, liquid and emulsion injectables in ampoules and vials, topicals, and sachets. The company was incorporated in 1990 and is headquartered in Chennai, India.

Corporate governance

CAPLIN POINT LABORATORIES LTD.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.